Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

0.1665 -0.0035 (-2.06%)
Streaming Delayed Price Updated: 1:05 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 204,614
Open 0.1734
Bid (Size) 0.1644 (3)
Ask (Size) 0.1665 (29)
Prev. Close 0.1700
Today's Range 0.1640 - 0.1755
52wk Range 0.1550 - 3.530
Shares Outstanding 64,483,958
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
From GlycoMimetics, Inc.
Via Business Wire
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace

Performance

YTD
-93.88%
-93.88%
1 Month
-10.00%
-10.00%
3 Month
-33.40%
-33.40%
6 Month
-94.22%
-94.22%
1 Year
-88.02%
-88.02%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why GlycoMimetics Stock is Trading Higher Monday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
From GlycoMimetics, Inc.
Via Business Wire
GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024
Via InvestorPlace
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
Via Benzinga
Why Is Acutus Medical (AFIB) Stock Down 41% Today?
Via InvestorPlace
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
Via InvestorPlace
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
From GlycoMimetics, Inc.
Via Business Wire
Earnings Scheduled For March 27, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.